Peer Review History

Original SubmissionDecember 21, 2022
Decision Letter - Ming-Ching Lee, Editor

PONE-D-22-33926Role of intrapulmonary lymph nodes in patients with NSCLC and visceral pleural invasion. The VPI 1314 multicenter registry study protocolPLOS ONE

Dear Dr. Minervini,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR: Four experts have reviewed the manuscript. Please explain in more details about the reviewer’s concerns and revise your paper. 

Please submit your revised manuscript by Apr 20 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ming-Ching Lee

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

4. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

********** 

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

********** 

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

********** 

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: No

********** 

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

********** 

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a well-written study protocol to retrospectively investigate the incidence of intraoperative lymph node metastasis and the association between intraoperative lymph node metastasis and visceral pleural invasion. Based on the recently revealed significant study results regarding sublobar resection (JCOG0802, CALGB140503), the use of sublobar resection has been increasing and is expected to increase further. To determine the extent of resection (sublobar resection or lobectomy), the presence of lymph node metastasis (occult lymph node metastasis) would be essential. Therefore, the results of this study will be of great importance to all thoracic surgeons. Vaghjiani et al. investigated occult lymph node metastasis in patients with clinical stage I lung cancer and found one-third of occult metastases located in intrapulmonary lymph nodes (Vaghjiani et al. J Thorac Oncol 2020). The findings of Vaghjiani’s study would be related to this study, which should be described in the Introduction or Discussion.

Reviewer #2: I red with interest the proposed protocol. It is well written ad focused on an actual and interesting matter regaradin lung cancer staging.

however, I have some criticisms that need author clarification.

1) which kind of lymphadenectomy are you planning for this study? for the study purpose I suggesto to insert a radical mediastinal dissection with almost 3 mediastinal nodal station dissected.

2) why do you prefer a zip file for data collection? Maybe for multicentric studies a web based dataset software is more fit.

Reviewer #3: the main issue I find is that unlike N2-nodes or even 10/11 nodes; the 12-14 nodes represent mainly the quality that is yielded from the pathology. Then becomes the issue of heterogeneity; as most centrest under report 12-14 nodes - compared to 11 nodes. So that is an insight into possible major bias. Thus; for reasoning - keep intrapulmonary nodes independent and other N1 nodes as divided.

Reviewer #4: Sample size: the formula for the prevalence estimation is not readable. Need justification of the allowable error. What is the 5-year survival rate? Will the cohort have enough events (298) during the study time?

Statistical analysis:

Should be “univariable” and “multivariable” instead of “univariate” and “multivariate”.

Which covariates will be included in the multivariable logistic regression?

What subgroups will be created for the KM analysis?

What if the non-informative censoring assumption is violated?

Need justification to use the RF for imputation? Will this imputation be used for outcome measures or covariates? Imputation will bring bias and a good approach requires a careful evaluation of the missing data mechanism and methods for imputation.

********** 

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Ilkka Ilonen

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to Reviewer #1:

Comment 1: This is a well-written study protocol to retrospectively investigate the incidence of intraoperative lymph node metastasis and the association between intraoperative lymph node metastasis and visceral pleural invasion. Based on the recently revealed significant study results regarding sublobar resection (JCOG0802, CALGB140503), the use of sublobar resection has been increasing and is expected to increase further. To determine the extent of resection (sublobar resection or lobectomy), the presence of lymph node metastasis (occult lymph node metastasis) would be essential. Therefore, the results of this study will be of great importance to all thoracic surgeons. Vaghjiani et al. investigated occult lymph node metastasis in patients with clinical stage I lung cancer and found one-third of occult metastases located in intrapulmonary lymph nodes (Vaghjiani et al. J Thorac Oncol 2020). The findings of Vaghjiani’s study would be related to this study, which should be described in the Introduction or Discussion.

Reply 1: we thank the reviewer for this comment which helped us to improve the manuscript. We have added the citation in the discussion

Response to Reviewer #2:

Comment 1: I red with interest the proposed protocol. It is well written ad focused on an actual and interesting matter regaradin lung cancer staging. however, I have some criticisms that need author clarification.

which kind of lymphadenectomy are you planning for this study? for the study purpose I suggesto to insert a radical mediastinal dissection with almost 3 mediastinal nodal station dissected.

Reply 1: dear Reviewer thanks for your comment. Indeed we added a sentence accepting your suggestion (“radical mediastinal lymphadenectomy with at least 6 lymph nodes from 3 mediastinal nodal stations”).

Comment 2: why do you prefer a zip file for data collection? Maybe for multicentric studies a web based dataset software is more fit.

Reply 2: thanks for this suggestion, we added a sentence in the section “ethical consideration”. We will use links to REDCAP Database provided by the principal investigator to the local investigators.

Response to Reviewer #3:

Comment 1: the main issue I find is that unlike N2-nodes or even 10/11 nodes; the 12-14 nodes represent mainly the quality that is yielded from the pathology. Then becomes the issue of heterogeneity; as most centres under report 12-14 nodes - compared to 11 nodes. So that is an insight into possible major bias. Thus; for reasoning - keep intrapulmonary nodes independent and other N1 nodes as divided.

Reply 1: dear Reviewer thanks a lot for your comment. In our real life scenario, the nodal stations 13/14 are often not analyzed and thus we would like to investigate if:
1- there is a percentage of patients which are nodal positive (stations 13/14) but they don’t receive adjuvant chemotherapy because the thoracic surgeons or the pathologists are not actively searching for the intraparenchymal nodes.

2- the worse OS and DFS of patients with NSCLC and visceral pleural invasion could be attributed to an unknown N1 Status of the intraparenchymal nodal stations.

In order to minimize the bias connected with the quality of the pathology, two seniors (>10 years experience) pathologists will examine the lymph nodes for the study purposes. The surgeon will dissect all the mediastinal lymphnodes trough a radical mediastinal lymphadenectomy during surgery and the pathologists will search for the lymph nodes station 13/14.

Response to Reviewer #4:

Comment 1: Sample size: the formula for the prevalence estimation is not readable. Need justification of the allowable error. What is the 5-year survival rate? Will the cohort have enough events (298) during the study time?

Reply 1: We thank the reviewer for raising this point. We re-inserted the formula and added a justification for the allowable error. According to the SEER database of American National Cancer Institute the 5-year survival for localized NSCLC is 61.2 % (https://seer.cancer.gov/statfacts/html/lungb.html). According to this number enough events should happen in the study time. However, we increased the minimal sample size by an additional 10% and added a sentence to the manuscript.

Comment 2: Should be “univariable” and “multivariable” instead of “univariate” and “multivariate”.

Reply 2: We thank the reviewer for catching this mistake. We have changed it throughout the manuscript

Comment 3: Which covariates will be included in the multivariable logistic regression?

Reply 3: Thank you for pointing this out. We will adjust for age, sex, and tumor characteristics (size, histology, and mutation status). We have added a sentence to the manuscript.

Comment 4: What subgroups will be created for the KM analysis?

Reply 4: Subgroups will include: presence of N1 metastasis (Yes/No), presence of metastasis in intrapulmonary lymph nodes (Yes/No), presence of pleural invasion (Yes/No), sex (male/female), and age (≥ median, < median).

Comment 5: What if the non-informative censoring assumption is violated?

Reply 5: Thank you very much for giving us the opportunity to describe this more in detail. If we find evidence of informative censoring, we will thoroughly investigate if there are variables that are related both to the outcome and the censoring. In case such relation is present, we will then adjust for the relevant variables and perform sensitivity analyses to evaluate the robustness of our findings to potential violations of the non-informative censoring assumption. We have added a description of this to the manuscript

Comment 6: Need justification to use the RF for imputation? Will this imputation be used for outcome measures or covariates? Imputation will bring bias and a good approach requires a careful evaluation of the missing data mechanism and methods for imputation

Reply 6: Thank you very much for raising this important point. We fully agree that a good approach is required when performing data imputation. Therefore, we added a more detailed description of the process. Also, since we plan to only impute the data where less than 5% of the data are missing the bias introduced by the imputation should be relatively small. The random forest based imputation algorithm was chosen because it performs similar to other modern imputation methods and can handle a wide variety of data types.

Attachments
Attachment
Submitted filename: Response to the reviewers.docx
Decision Letter - Ming-Ching Lee, Editor

Role of intrapulmonary lymph nodes in patients with NSCLC and visceral pleural invasion. The VPI 1314 multicenter registry study protocol

PONE-D-22-33926R1

Dear Dr. Minervini,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ming-Ching Lee

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I appreciate that the authors revised their paper appropriately. I do not have any further comments.

Reviewer #2: The authors answered clearly to my comments. I think this is an interesting protocol and I', courious to see their results.

Reviewer #3: all concerns are addressed satisfactorilrly. I wish all the best to the authors and to the project presented

Reviewer #4: All my concerns were addressed.

The statistical section is acceptable.

I think the protocol is good for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

**********

Formally Accepted
Acceptance Letter - Ming-Ching Lee, Editor

PONE-D-22-33926R1

Role of intrapulmonary lymph nodes in patients with NSCLC and visceral pleural invasion. The VPI 1314 multicenter registry study protocol

Dear Dr. Minervini:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ming-Ching Lee

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .